We proposed the chemoimmunotherapeutic strategy by synergizing PTX with the immunomodulator MMST to recruit CD4+ T helper cells and cytotoxic CD8+ T cells (Figure 5), and to restrict the escape of cancer cells from immunosurveillance, as immune cells are considered to be the most important factor throughout breast carcinogenesis [95]. This evidence concerns the gene CD8A and cancer.